Savara Inc. (NASDAQ:SVRA) Q3 2018 Earnings Conference Call - Final Transcript
Nov 07, 2018 • 05:30 pm ET
Welcome to the Savara Conference Call. At this time, all participants are in listen-only mode. An audio webcast of this call will be available on the Investors section of Savara's website at savarapharma.com. This call is subject to copyright and is the property of Savara. All recordings, reproduction or transmission of this call without the expressed written consent of Savara is strictly prohibited. As a reminder, today's call is being recorded.
I would now like to turn the phone over to Anne Erickson, the new Head of IR and Corporate Communications at Savara.
Good afternoon, and thank you for joining us. I'm happy to be on board at Savara at such a dynamic time for the company, and I look forward to speaking with many of you in the coming months. A press release reporting our third quarter 2018 financial results was issued earlier today, November 7, 2018, and can be found on the Investors section of our website at savarapharma.com. If you have not received this release or if you'd like to be added to the company's distribution list, please e-mail me at email@example.com. This call is also being webcast live over the Internet, and a replay will be available on the company's website for the next 30 days with the telephone replay available through November 12.
(Forward-Looking Cautionary Statements)
As usual, we will field analyst questions at the end of the call. However, we would like to encourage our shareholders on the call to submit questions via e-mail to firstname.lastname@example.org. Time permitting, we will address these questions and others recently received by the IR team. Joining me on the call today are Rob Neville, CEO; Taneli Jouhikainen, COO; and Dave Lowrance, CFO.
I'll now turn the call over to Rob.
Thank you, Anne, and we're very excited to have you on board. And welcome, everybody to our third quarter call for 2018. Today, I'll provide you with an update on the business and a brief recap of the quarter's highlights. Q3 was an eventful and dynamic quarter on a number of fronts. We made substantial progress against our corporate priorities, while advancing our clinical development programs, supporting the patient communities we serve and engaging in activities that will enable Savara's transition to a commercial entity. We look forward to continuing this momentum as we forge ahead.
On the clinical development front, we successfully completed patient enrollment in the two Molgradex studies. We are proud of the committed physicians and study coordinators working on these important programs and of course, extend our deepest gratitude to the patients, whose participation make these studies possible.
With the IMPALA study, last month, we completed patient enrollment with the final count of 139 randomized patients across 34 study sites in the US. This makes IMPALA by far the largest clinical study ever conducted in aPAP patients, and we're excited to be leading this multinational endeavor. Hitting the target enrollment in the IMPALA study within a couple of weeks of our stated guidance was a